Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Janssen Pharmaceuticals
Biotech
J&J halts enrollment in trial of AC Immune Alzheimer's drug
Analysts speculated recruitment challenges may be behind the decision.
James Waldron
Feb 19, 2026 9:50am
J&J drops Addex epilepsy drug after reviewing phase 2 failure
Jul 18, 2024 5:17am
Addex's Janssen-partnered epilepsy drug fails phase 2 trial
Apr 29, 2024 8:44am
Cidara regains rights to flu med from Janssen, divests Rezzayo
Apr 24, 2024 4:05pm
MeiraGTx gifts last of gene therapy rights to J&J for $415M
Dec 21, 2023 10:14am
SU2C gives out 7 grants to boost diversity in cancer trials
Sep 26, 2023 11:01am
